Angiotensin II receptor antagonist, L-158,809, prevents intimal hyperplasia in dog grafted veins

被引:22
|
作者
Yuda, A
Takai, S
Jin, D
Sawada, Y
Nishimoto, M
Matsuyama, N
Asada, K
Kondo, K
Sasaki, S
Miyazaki, M [1 ]
机构
[1] Osaka Med Coll, Dept Pharmacol, Takatsuki, Osaka 5698686, Japan
[2] Osaka Med Coll, Dept Thorac & Cardiovasc Surg, Takatsuki, Osaka 5698686, Japan
关键词
angiotensin II; chymase; angiotensin converting enzyme; graft;
D O I
10.1016/S0024-3205(00)00910-3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
We investigated the levels of the angiotensin II-forming enzymes, chymase and angiotensin converting enzyme (ACE), in dog grafted veins, and studied the effect of an angiotensin II type 1 receptor antagonist, L-158,809, on vascular proliferation in the grafted veins. The right external jugular vein was grafted to the ipsilaterial carotid artery. In the group treated with L-158,809, the drug (10 mg/kg per day, p.o.) were administered orally from 7 days before the operation to 28 days after it, while the others were administrated placebo. In the placebo-treated group, the chymase activity in the grafted veins was increased about 10-fold and the ACE activity was doubled. The areas of intima and media were significantly increased in the grafted veins in the placebo-treated group. L-158,809 significantly reduced the intimal area of the grafted veins. An angiotensin II receptor antagonist, 1,-158,809, prevented the vascular proliferation in the grafted veins, and the development of the-proliferation may depend on activation of local angiotensin II formation. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:41 / 48
页数:8
相关论文
共 50 条
  • [1] Angiotensin II receptor antagonist, L-158,809, prevents neointima formation in dog grafted veins
    Yuda, A
    Takai, S
    Jin, D
    Nishimoto, M
    Sawada, Y
    Sasaki, S
    Miyazaki, M
    JOURNAL OF HYPERTENSION, 2000, 18 : S82 - S82
  • [2] DISPOSITION OF THE ANGIOTENSIN-II RECEPTOR ANTAGONIST L-158,809 IN RATS AND RHESUS-MONKEYS
    COLLETTI, AE
    KRIETER, PA
    DRUG METABOLISM AND DISPOSITION, 1994, 22 (02) : 183 - 188
  • [3] PHARMACOLOGICAL CHARACTERIZATION OF L-158,809, A NONPEPTIDE ANGIOTENSIN-AT(1) RECEPTOR ANTAGONIST
    JAISWAL, N
    KHOSLA, MC
    FASEB JOURNAL, 1993, 7 (07): : A1149 - A1149
  • [4] Cardiac hypertrophy in copper-deficient rats is not attenuated by angiotensin II receptor antagonist L-158,809
    Lear, PM
    Heller, LJ
    Prohaska, JR
    PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 1996, 212 (03): : 284 - 292
  • [5] INVITRO PHARMACOLOGY OF L-158,809, A NEW HIGHLY POTENT AND SELECTIVE ANGIOTENSIN-II RECEPTOR ANTAGONIST
    CHANG, RSL
    SIEGL, PKS
    CLINESCHMIDT, BV
    MANTLO, NB
    CHAKRAVARTY, PK
    GREENLEE, WJ
    PATCHETT, AA
    LOTTI, VJ
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1992, 262 (01): : 133 - 138
  • [6] INVIVO PHARMACOLOGY OF A HIGHLY POTENT AND SELECTIVE NONPEPTIDE ANGIOTENSIN-II (AII) RECEPTOR ANTAGONIST - L-158,809
    SIEGL, PKS
    CHANG, RS
    GREENLEE, WJ
    LOTTI, VJ
    MANTLO, NB
    PATCHETT, AA
    SWEET, CS
    FASEB JOURNAL, 1991, 5 (06): : A1576 - A1576
  • [7] INVIVO PHARMACOLOGY OF L-158,809, A NEW HIGHLY POTENT AND SELECTIVE NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST
    SIEGL, PKS
    CHANG, RSL
    MANTLO, NB
    CHAKRAVARTY, PK
    ONDEYKA, DL
    GREENLEE, WJ
    PATCHETT, AA
    SWEET, CS
    LOTTI, VJ
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1992, 262 (01): : 139 - 144
  • [8] INVITRO PHARMACOLOGY OF A HIGHLY POTENT AND SELECTIVE NONPEPTIDE ANGIOTENSIN-II (AII) RECEPTOR ANTAGONIST - L-158,809
    CHANG, RSL
    SIEGL, PKS
    CLINESCHMIDT, BV
    MANTLO, NB
    CHAKRAVARTY, PK
    GREENLEE, WJ
    PATCHETT, AA
    LOTTI, VJ
    FASEB JOURNAL, 1991, 5 (06): : A1575 - A1575
  • [9] Captopril but not angiotensin II receptor antagonist L158,809 prevents cognitive impairment.
    Skinner, MH
    Tan, DX
    Jamieson, MJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 156 - 156
  • [10] Effect of the novel angiotensin II type 1 receptor antagonist L-158,809 on acute infarct expansion and acute anterior myocardial infarction in the dog
    Ford, WR
    Khan, MI
    Jugdutt, BI
    CANADIAN JOURNAL OF CARDIOLOGY, 1998, 14 (01) : 73 - 80